Experienced in Iron Deficiency Anemia

Dr. Angela T. Alistar

Hematology Oncology | Hematology | Oncology
Practice Associates Medical Group
100 Madison Ave, 
Morristown, NJ 
Clinical Trials:Currently Recruiting for 2 Trials
Offers Telehealth
Experienced in Iron Deficiency Anemia
Practice Associates Medical Group
100 Madison Ave, 
Morristown, NJ 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Angela Alistar is a Hematologist Oncology specialist and a Hematologist in Morristown, New Jersey. Dr. Alistar is rated as an Experienced provider by MediFind in the treatment of Iron Deficiency Anemia. Her top areas of expertise are Pancreatic Cancer, Familial Pancreatic Cancer, Colorectal Cancer, and Stomach Cancer.

Her clinical research consists of co-authoring 17 peer reviewed articles and participating in 31 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in NC
Hospital Affiliations
Morristown Medical Center
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 6 Less Insurance Carriers -

Locations

PRACTICE ASSOCIATES MEDICAL GROUP
100 Madison Ave, Morristown, NJ 07960

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

29 Clinical Trials

Targeted Intra-arterial Gemcitabine vs. Continuation of IV Gemcitabine Plus Nab-Paclitaxel Following Induction With Sequential IV Gemcitabine Plus Nab-Paclitaxel and Radiotherapy for Locally Advanced Pancreatic Cancer
Targeted Intra-arterial Gemcitabine vs. Continuation of IV Gemcitabine Plus Nab-Paclitaxel Following Induction With Sequential IV Gemcitabine Plus Nab-Paclitaxel and Radiotherapy for Locally Advanced Pancreatic Cancer
Enrollment Status: Recruiting
Publish Date: April 15, 2025
Intervention Type: Drug, Device
Study Drugs: Gemcitabine, Nab-paclitaxel
Study Phase: Phase 3
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Patients With Select Solid Tumors
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Patients With Select Solid Tumors
Enrollment Status: Recruiting
Publish Date: March 26, 2025
Intervention Type: Biological
Study Drugs: VV1, Cemiplimab
Study Phase: Phase 2
A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
Randomized Phase II Study of 2nd Line FOLFIRI Versus Modified FOLFIRI With PARP Inhibitor ABT-888 (Veliparib) (NSC-737664) in Metastatic Pancreatic Cancer
Randomized Phase II Study of 2nd Line FOLFIRI Versus Modified FOLFIRI With PARP Inhibitor ABT-888 (Veliparib) (NSC-737664) in Metastatic Pancreatic Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Drug, Other
Study Drugs: Fluorouracil, Irinotecan Hydrochloride, Leucovorin Calcium, Veliparib
Study Phase: Phase 2
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Procedure, Drug
Study Drugs: Atezolizumab, 5-Fluorouracil, Leucovorin, Oxaliplatin
Study Phase: Phase 3
Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer
Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 05, 2025
Intervention Type: Other, Procedure, Drug, Biological
Study Phase: Phase 3
Prospective, Single Arm Medical Food Study to Evaluate a Standardized Nonessential Amino Acid Restriction (NEAAR) Medical Food for the Dietary Management of Advanced/Metastatic Pancreatic Cancer
Prospective, Single Arm Medical Food Study to Evaluate a Standardized Nonessential Amino Acid Restriction (NEAAR) Medical Food for the Dietary Management of Advanced/Metastatic Pancreatic Cancer
Enrollment Status: Completed
Publish Date: July 18, 2025
Intervention Type: Other
Study Phase: Not Applicable
A Phase 2/3, Randomized, Open-Label Study of Maintenance GRT-C901/GRT-R902, A Neoantigen Vaccine, in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer
A Phase 2/3, Randomized, Open-Label Study of Maintenance GRT-C901/GRT-R902, A Neoantigen Vaccine, in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: May 16, 2025
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES)
A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES)
Enrollment Status: Active_not_recruiting
Publish Date: March 30, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Phase 2 Study of BPM31510 (Ubidecarenone, USP) Nanosuspension Injection Administered Intravenously With Gemcitabine as 2nd/3rdline Therapy in Advanced Pancreatic Cancer Patients
A Phase 2 Study of BPM31510 (Ubidecarenone, USP) Nanosuspension Injection Administered Intravenously With Gemcitabine as 2nd/3rdline Therapy in Advanced Pancreatic Cancer Patients
Enrollment Status: Completed
Publish Date: March 26, 2025
Intervention Type: Drug
Study Phase: Phase 2
Phase 1 Open-Label Dose Escalation Study of BDB001 as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
Phase 1 Open-Label Dose Escalation Study of BDB001 as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: March 26, 2025
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1/2, Open-Label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of an Anti-CTLA-4 Human Monoclonal Antibody (AGEN1884) in Subjects With Advanced or Refractory Cancer and in Subjects Who Have Progressed During Treatment With a PD-1/PD-L1 Inhibitor as Their Most Recent Therapy
A Phase 1/2, Open-Label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of an Anti-CTLA-4 Human Monoclonal Antibody (AGEN1884) in Subjects With Advanced or Refractory Cancer and in Subjects Who Have Progressed During Treatment With a PD-1/PD-L1 Inhibitor as Their Most Recent Therapy
Enrollment Status: Completed
Publish Date: March 17, 2025
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Randomized Phase II Trial of Two Different Nutritional Approaches for Patients Receiving Treatment for Their Advanced Pancreatic Cancer
Randomized Phase II Trial of Two Different Nutritional Approaches for Patients Receiving Treatment for Their Advanced Pancreatic Cancer
Enrollment Status: Completed
Publish Date: February 21, 2025
Intervention Type: Other
Study Phase: Not Applicable
Phase I/IIA Safety and Efficacy Study of IMSA101 in Patients With Advanced Treatment-Refractory Malignancies
Phase I/IIA Safety and Efficacy Study of IMSA101 in Patients With Advanced Treatment-Refractory Malignancies
Enrollment Status: Completed
Publish Date: December 11, 2024
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 1 PK and Dose Escalation and Expansion Study of DST-2970 in Patients With Prostate Cancer With Rising PSA on Treatment With Abiraterone Acetate
A Phase 1 PK and Dose Escalation and Expansion Study of DST-2970 in Patients With Prostate Cancer With Rising PSA on Treatment With Abiraterone Acetate
Enrollment Status: Terminated
Publish Date: October 17, 2024
Intervention Type: Drug
Study Drugs: Abiraterone Acetate, Prednisone, Abiraterone
Study Phase: Phase 1
A Phase IIa, Multicenter, Open-label Study to Assess the Safety and Efficacy of the Combination of BL-8040 and Pembrolizumab in Patients With Metastatic Pancreatic Cancer, the COMBAT Study (KEYNOTE-202)
A Phase IIa, Multicenter, Open-label Study to Assess the Safety and Efficacy of the Combination of BL-8040 and Pembrolizumab in Patients With Metastatic Pancreatic Cancer, the COMBAT Study (KEYNOTE-202)
Enrollment Status: Completed
Publish Date: August 28, 2024
Intervention Type: Drug
Study Drugs: BL-8040, Pembrolizumab, Chemotherapy of Onivyde
Study Phase: Phase 2
A Multi-Center Randomized Phase IB/II Study of Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)
A Multi-Center Randomized Phase IB/II Study of Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)
Enrollment Status: Completed
Publish Date: July 11, 2024
Intervention Type: Drug
Study Drugs: CPI 613, Gemcitabine, Cisplatin
Study Phase: Phase 1/Phase 2
A Randomized Phase II Trial to Evaluate the Efficacy of Supportive Therapy With Ginseng for Patients on Treatment With Regorafenib
A Randomized Phase II Trial to Evaluate the Efficacy of Supportive Therapy With Ginseng for Patients on Treatment With Regorafenib
Enrollment Status: Terminated
Publish Date: June 26, 2024
Intervention Type: Dietary supplement, Drug
Study Phase: Phase 2
A Single Arm, Multi-center Phase 2 Trial of mFOLFOX6 + Trastuzumab + Avelumab in First-line, Metastatic, HER2-amplified Gastric and Esophageal Adenocarcinomas
A Single Arm, Multi-center Phase 2 Trial of mFOLFOX6 + Trastuzumab + Avelumab in First-line, Metastatic, HER2-amplified Gastric and Esophageal Adenocarcinomas
Enrollment Status: Completed
Publish Date: December 19, 2023
Intervention Type: Drug
Study Drugs: Oxaliplatin, Leucovorin, 5 fluorouracil, Trastuzumab, Avelumab
Study Phase: Phase 2
A Phase I Clinical Trial of Fluorouracil (5-FU) + CPI-613 Combination in Previously Treated Metastatic Colorectal Cancer Patients
A Phase I Clinical Trial of Fluorouracil (5-FU) + CPI-613 Combination in Previously Treated Metastatic Colorectal Cancer Patients
Enrollment Status: Completed
Publish Date: August 07, 2023
Intervention Type: Drug, Other
Study Drugs: 6,8-Bis(benzylthio)octanoic acid, Fluorouracil
Study Phase: Phase 1
A Phase I Open-Label Dose-Escalation Clinical Trial of CPI-613 in Combination With Modified FOLFIRINOX in Patients With Metastatic Pancreatic Cancer and Good Performance Status
A Phase I Open-Label Dose-Escalation Clinical Trial of CPI-613 in Combination With Modified FOLFIRINOX in Patients With Metastatic Pancreatic Cancer and Good Performance Status
Enrollment Status: Completed
Publish Date: July 12, 2023
Intervention Type: Drug, Other
Study Drugs: 6,8-Bis(Benzylthio)Octanoic Acid, Oxaliplatin, Leucovorin, Irinotecan, 5-Fluorouracil
Study Phase: Phase 1
A Phase 2, Open-label, Multi-Arm Trial to Evaluate the Efficacy and Safety of BDB001 in the Treatment of Subjects With Advanced Solid Tumors That Have Progressed on Anti-PD-1 or Anti-PD-L1 mAb Treatment
A Phase 2, Open-label, Multi-Arm Trial to Evaluate the Efficacy and Safety of BDB001 in the Treatment of Subjects With Advanced Solid Tumors That Have Progressed on Anti-PD-1 or Anti-PD-L1 mAb Treatment
Enrollment Status: Completed
Publish Date: June 18, 2023
Intervention Type: Drug
Study Phase: Phase 2
Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ramucirumab and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein (AFP) Following First-Line Therapy With Sorafenib
Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ramucirumab and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein (AFP) Following First-Line Therapy With Sorafenib
Enrollment Status: Completed
Publish Date: January 20, 2023
Intervention Type: Drug
Study Drug: Ramucirumab
Study Phase: Phase 3
A Phase III Multicenter Open-label Randomized Trial to Evaluate Efficacy and Safety of Folfirinox (FFX) Versus Combination of CPI-613 With Modified Folfirinox (mFFX) in Patients With Metastatic Adenocarcinoma of the Pancreas
A Phase III Multicenter Open-label Randomized Trial to Evaluate Efficacy and Safety of Folfirinox (FFX) Versus Combination of CPI-613 With Modified Folfirinox (mFFX) in Patients With Metastatic Adenocarcinoma of the Pancreas
Enrollment Status: Completed
Publish Date: January 03, 2023
Intervention Type: Drug
Study Drugs: CPI 613, mFolfirinox, Folfirinox
Study Phase: Phase 3
A SU2C Catalyst ® Randomized Phase II Trial of the PD1 Inhibitor Pembrolizumab With or Without a Vitamin D Receptor Agonist Paricalcitol in Patients With Stage IV Pancreatic Cancer Who Have Been Placed in Best Possible Response
A SU2C Catalyst ® Randomized Phase II Trial of the PD1 Inhibitor Pembrolizumab With or Without a Vitamin D Receptor Agonist Paricalcitol in Patients With Stage IV Pancreatic Cancer Who Have Been Placed in Best Possible Response
Enrollment Status: Completed
Publish Date: December 27, 2022
Intervention Type: Drug
Study Phase: Phase 2
Preoperative Extended Chemotherapy vs. Chemotherapy Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Head of the Pancreas
Preoperative Extended Chemotherapy vs. Chemotherapy Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Head of the Pancreas
Enrollment Status: Unknown
Publish Date: May 24, 2022
Intervention Type: Drug, Procedure, Radiation
Study Drugs: mFOLFIRINOX, FOLFOX
Study Phase: Phase 2
A Pilot Open-Label Clinical Trial of CPI-613 in Patients With Advanced Bile Duct Cancers
A Pilot Open-Label Clinical Trial of CPI-613 in Patients With Advanced Bile Duct Cancers
Enrollment Status: Completed
Publish Date: May 15, 2019
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Pilot Study: Open-Label Clinical Trial of CPI-613 in Patients With Metastatic Pancreatic Adenocarcinoma and Poor Performance Status
A Pilot Study: Open-Label Clinical Trial of CPI-613 in Patients With Metastatic Pancreatic Adenocarcinoma and Poor Performance Status
Enrollment Status: Completed
Publish Date: December 27, 2018
Intervention Type: Drug
Study Phase: Phase 1
Precision Medicine for Patients With Malignancy at the Comprehensive Cancer Center of Wake Forest University
Precision Medicine for Patients With Malignancy at the Comprehensive Cancer Center of Wake Forest University
Enrollment Status: Terminated
Publish Date: July 02, 2018
Intervention Type: Other
Study Phase: Not Applicable
View 27 Less Clinical Trials

17 Total Publications

Phase 1 first-in-human dose-escalation study of IMSA101, a novel cyclic di-nucleotide STING agonist, for patients with advanced solid tumor malignancies.
Phase 1 first-in-human dose-escalation study of IMSA101, a novel cyclic di-nucleotide STING agonist, for patients with advanced solid tumor malignancies.
Journal: Journal for immunotherapy of cancer
Published: May 29, 2025
Similar Doctors
Distinguished in Iron Deficiency Anemia
Dr. Mikhail G. Grinberg
Hematology Oncology | Hematology | Oncology
Distinguished in Iron Deficiency Anemia
Dr. Mikhail G. Grinberg
Hematology Oncology | Hematology | Oncology

Hematology Oncology Associates Of Brooklyn, Llp

1660 E 14th St, Suite 401, 
Brooklyn, NY 
 (29.3 miles away)
718-382-8500
Languages Spoken:
English
See accepted insurances

Mikhail Grinberg is a Hematologist Oncology specialist and a Hematologist in Brooklyn, New York. Dr. Grinberg is rated as a Distinguished provider by MediFind in the treatment of Iron Deficiency Anemia. His top areas of expertise are Childhood Iron Deficiency Anemia, Iron Deficiency Anemia, Glossitis, and Pernicious Anemia.

Distinguished in Iron Deficiency Anemia
Dr. Fazal Bari
Hematology | Oncology | Hematology Oncology
Distinguished in Iron Deficiency Anemia
Dr. Fazal Bari
Hematology | Oncology | Hematology Oncology

Oncology And Hematology Specialists,p.a.

100 Madison Ave, Suite 3101, 
Morristown, NJ 
 (0.1 miles away)
973-267-9543
Languages Spoken:
English, Spanish, Urdu
See accepted insurances
Accepting New Patients

Fazal Bari is a Hematologist and an Oncologist in Morristown, New Jersey. Dr. Bari is rated as a Distinguished provider by MediFind in the treatment of Iron Deficiency Anemia. His top areas of expertise are Paget Disease of the Breast, Childhood Iron Deficiency Anemia, Iron Deficiency Anemia, and Colorectal Cancer. Dr. Bari is currently accepting new patients.

Distinguished in Iron Deficiency Anemia
Dr. Joseph Lebowicz
Hematology Oncology | Hematology | Oncology
Distinguished in Iron Deficiency Anemia
Dr. Joseph Lebowicz
Hematology Oncology | Hematology | Oncology

Hematology Oncology Associates Of Brooklyn, Llp

1660 E 14th St, Suite 401, 
Brooklyn, NY 
 (29.3 miles away)
718-382-8500
Languages Spoken:
English
See accepted insurances

Joseph Lebowicz is a Hematologist Oncology specialist and a Hematologist in Brooklyn, New York. Dr. Lebowicz is rated as a Distinguished provider by MediFind in the treatment of Iron Deficiency Anemia. His top areas of expertise are Childhood Iron Deficiency Anemia, Iron Deficiency Anemia, Glossitis, and Pernicious Anemia.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Alistar's expertise for a condition
ConditionClose
View All 29 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile